Dr. James Cusack
View Contact Information
Schedule a Conversation with a HIPEC Surgeon
The surgeon or staff member will make their best effort to call you at your requested time. If they become unavailable you will receive a text.
Board certification by an ABMS Member Board is the premier, independently assessed credential attainable in medicine today.
The University of Texas MD Anderson Cancer Center
James Cusack, MD, FACS, is a graduate of Dartmouth College and Emory University Medical School who trained in surgery at Tufts-New England Medical Center. He completed a Research Fellowship at Brigham and Women's Hospital and the Surgical Oncology Fellowship at M D Anderson Cancer Center. In 2000 he joined the staff at Massachusetts General, the faculty of Harvard Medical School, and the consulting staff at Dana-Farber Cancer Institute. At Massachusetts General, he is Director of the Peritoneal Surface Malignancy (HIPEC) Program. He served on the Executive Council of the Society of Surgical Oncology (SSO) and was Chair of the SSO Scientific Program Committee. He also served on the American Society of Clinical Oncology Gastrointestinal Symposium Program Committee. Among Dr. Cusack's awards for his patient care are Boston Super Doctors, Boston Top Doctors, The MGH One Hundred, America's Top Surgeons, America's Top Doctors for Cancer, and Patients' Choice Award.
The Cusack Laboratory has made landmark contributions to the understanding of molecular mechanisms of chemotherapy resistance. Since 1995 Dr. Cusack's research has been funded by NIH, American Cancer Society, biotech collaborators, and his patients. Ongoing research topics are biomarkers of resistance and new targets for therapeutic intervention in colorectal and appendix cancer, melanoma, and Merkel Cell carcinoma. His bibliography lists over 70 publications, and he serves on numerous editorial boards. Dr. Cusack is the Director of the MGH Global Surgery Initiative and Co-Chair of the MGH Cancer Center Global Health Committee. Dr. Cusack is committed to improving access to affordable surgical treatment and multidisciplinary cancer care in resource-limited settings, especially the East African Community.
- ‘Hot Chemotherapy’ Generates Heated Debate about Its Use with Cytoreductive Surgery to Manage Peritoneal Metastases
Abstracts Authored by Dr. Cusack
- A critical look at local-regional management of peritoneal metastasis.
- Treatment of Peritoneal Carcinomatosis of Colorectal Origin
- Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery.